Submit Manuscript  

Article Details


Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial

[ Vol. 18 , Issue. 2 ]

Author(s):

Haoyu Meng, Bo Chen, Zhengxian Tao, Zhihui Xu, Liansheng Wang, Ju Weizhu, Yongyong Hong, Xiang Liu, Hua Wang, Lisheng Wang, Zuze Wu and Zhijian Yang*   Pages 125 - 130 ( 6 )

Abstract:


Objective: Our previous phase I clinical trial has confirmed the safety of Adenovirus carrying Hepatocyte Growth Factor gene (Ad-HGF) by intracoronary administration for treating severe coronary artery disease. This study was performed to evaluate the safety and efficacy of Ad-HGF by percutaneous endocardial injection for treating post-infarct heart failure.

Methods: A total of 30 patients (15 in the experimental group and 15 in the control group) with postinfarct heart failure who were not indicated to revascularization and had received the optimal standardized medication therapy were included in the study. Percutaneous endocardial Ad-HGF gene transfer was injected with a catheter-based intramyocardial delivery system in the experimental group. Safety parameters were measured and compared between baseline and follow-ups in the experimental group. The Mean Difference (MD) of efficacy parameters from baseline to 6-month follow-up was measured in both groups and compared with each other.

Results: No one suffered from serious adverse events in the experimental group during the 6-month follow-up. The experimental group revealed significant lower left ventricular end-diastolic dimension (LVDd) (68.5 vs. 65.8 MD: -2.69±1.08, P=0.03) and higher LVEF of both echocardiograph (35.2 vs. 39.3, MD: 4.05±0.86, P=0.0005) and single photon emission computed tomography (27.7 vs. 30.6, MD: 2.9±0.8, P=0.003) in the 6-month follow-up than that in the baseline, but the control group did not (P>0.05). Compared to the control group, the experimental group showed significant improvement ranges of lower LVDd (2.6 vs. -2.69, MD: -5.3±1.4, P=0.0009) and higher echocardiographic LVEF (-2 vs. 4.05, MD: 6.1±1.6, P=0.0008) from baseline to 6-month follow-up.

Conclusion: Percutaneous endocardial administration of Ad-HGF is safe and potentially efficient in improving LVEF and lowering LVDd of patients with post-infarct heart failure.

Keywords:

Gene therapy, Hepatocyte growth factor, Post-infarct heart failure, Percutaneous endocardial administration, Ad- HGF, Echocardiographic.

Affiliation:

Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, Department of Technological, MicroPort Medical Co. Ltd., Shanghai, Department of Experimental Hematology, Beijing Institute of Radiation Medicine of China, Academy of Military Medical Sciences, Beijing, Department of Experimental Hematology, Beijing Institute of Radiation Medicine of China, Academy of Military Medical Sciences, Beijing, Department of Experimental Hematology, Beijing Institute of Radiation Medicine of China, Academy of Military Medical Sciences, Beijing, Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu



Read Full-Text article